Meloxicam increases epidermal growth factor receptor expression improving survival after hepatic resection in diet-induced obese mice

Xiaoling Jin, Teresa Zimmers, Yanlin Jiang, Daniel P. Milgrom, Zongxiu Zhang, Leonidas Koniaris

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Patients with fatty liver have delayed regenerative responses, increased hepatocellular injury, and increased risk for perioperative mortality. Currently, no clinical therapy exists to prevent liver failure or improve regeneration in patients with fatty liver. Previously we demonstrated that obese mice have markedly reduced levels of epidermal growth factor receptor in liver. We sought to identify pharmacologic agents to increase epidermal growth factor receptor expression to improve hepatic regeneration in the setting of fatty liver resection. Methods: Lean (20% calories from fat) and diet-induced obese mice (60% calories from fat) were subjected to 70% or 80% hepatectomy. Results: Using the BaseSpace Correlation Engine of deposited gene arrays we identified agents that increased hepatic epidermal growth factor receptor. Meloxicam was identified as inducing epidermal growth factor receptor expression across species. Meloxicam improved hepatic steatosis in diet-induced obese mice both grossly and histologically. Immunohistochemistry and Western blot analysis demonstrated that meloxicam pretreatment of diet-induced obese mice dramatically increased epidermal growth factor receptor protein expression in hepatocytes. After 70% hepatectomy, meloxicam pretreatment ameliorated liver injury and significantly accelerated mitotic rates of hepatocytes in obese mice. Recovery of liver mass was accelerated in obese mice pretreated with meloxicam (by 26% at 24 hours and 38% at 48 hours, respectively). After 80% hepatectomy, survival was dramatically increased with meloxicam treatment. Conclusion: Low epidermal growth factor receptor expression is a common feature of fatty liver disease. Meloxicam restores epidermal growth factor receptor expression in steatotic hepatocytes. Meloxicam pretreatment may be applied to improve outcome after fatty liver resection or transplantation with steatotic graft.

Original languageEnglish (US)
JournalSurgery (United States)
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

meloxicam
Obese Mice
Epidermal Growth Factor Receptor
Diet
Fatty Liver
Survival
Liver
Hepatectomy
Hepatocytes
Regeneration
Fats
Liver Failure
Wounds and Injuries

ASJC Scopus subject areas

  • Surgery

Cite this

Meloxicam increases epidermal growth factor receptor expression improving survival after hepatic resection in diet-induced obese mice. / Jin, Xiaoling; Zimmers, Teresa; Jiang, Yanlin; Milgrom, Daniel P.; Zhang, Zongxiu; Koniaris, Leonidas.

In: Surgery (United States), 01.01.2018.

Research output: Contribution to journalArticle

@article{c104b9b151a14c2f9d5df332089549a4,
title = "Meloxicam increases epidermal growth factor receptor expression improving survival after hepatic resection in diet-induced obese mice",
abstract = "Background: Patients with fatty liver have delayed regenerative responses, increased hepatocellular injury, and increased risk for perioperative mortality. Currently, no clinical therapy exists to prevent liver failure or improve regeneration in patients with fatty liver. Previously we demonstrated that obese mice have markedly reduced levels of epidermal growth factor receptor in liver. We sought to identify pharmacologic agents to increase epidermal growth factor receptor expression to improve hepatic regeneration in the setting of fatty liver resection. Methods: Lean (20{\%} calories from fat) and diet-induced obese mice (60{\%} calories from fat) were subjected to 70{\%} or 80{\%} hepatectomy. Results: Using the BaseSpace Correlation Engine of deposited gene arrays we identified agents that increased hepatic epidermal growth factor receptor. Meloxicam was identified as inducing epidermal growth factor receptor expression across species. Meloxicam improved hepatic steatosis in diet-induced obese mice both grossly and histologically. Immunohistochemistry and Western blot analysis demonstrated that meloxicam pretreatment of diet-induced obese mice dramatically increased epidermal growth factor receptor protein expression in hepatocytes. After 70{\%} hepatectomy, meloxicam pretreatment ameliorated liver injury and significantly accelerated mitotic rates of hepatocytes in obese mice. Recovery of liver mass was accelerated in obese mice pretreated with meloxicam (by 26{\%} at 24 hours and 38{\%} at 48 hours, respectively). After 80{\%} hepatectomy, survival was dramatically increased with meloxicam treatment. Conclusion: Low epidermal growth factor receptor expression is a common feature of fatty liver disease. Meloxicam restores epidermal growth factor receptor expression in steatotic hepatocytes. Meloxicam pretreatment may be applied to improve outcome after fatty liver resection or transplantation with steatotic graft.",
author = "Xiaoling Jin and Teresa Zimmers and Yanlin Jiang and Milgrom, {Daniel P.} and Zongxiu Zhang and Leonidas Koniaris",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.surg.2017.11.029",
language = "English (US)",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Meloxicam increases epidermal growth factor receptor expression improving survival after hepatic resection in diet-induced obese mice

AU - Jin, Xiaoling

AU - Zimmers, Teresa

AU - Jiang, Yanlin

AU - Milgrom, Daniel P.

AU - Zhang, Zongxiu

AU - Koniaris, Leonidas

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Patients with fatty liver have delayed regenerative responses, increased hepatocellular injury, and increased risk for perioperative mortality. Currently, no clinical therapy exists to prevent liver failure or improve regeneration in patients with fatty liver. Previously we demonstrated that obese mice have markedly reduced levels of epidermal growth factor receptor in liver. We sought to identify pharmacologic agents to increase epidermal growth factor receptor expression to improve hepatic regeneration in the setting of fatty liver resection. Methods: Lean (20% calories from fat) and diet-induced obese mice (60% calories from fat) were subjected to 70% or 80% hepatectomy. Results: Using the BaseSpace Correlation Engine of deposited gene arrays we identified agents that increased hepatic epidermal growth factor receptor. Meloxicam was identified as inducing epidermal growth factor receptor expression across species. Meloxicam improved hepatic steatosis in diet-induced obese mice both grossly and histologically. Immunohistochemistry and Western blot analysis demonstrated that meloxicam pretreatment of diet-induced obese mice dramatically increased epidermal growth factor receptor protein expression in hepatocytes. After 70% hepatectomy, meloxicam pretreatment ameliorated liver injury and significantly accelerated mitotic rates of hepatocytes in obese mice. Recovery of liver mass was accelerated in obese mice pretreated with meloxicam (by 26% at 24 hours and 38% at 48 hours, respectively). After 80% hepatectomy, survival was dramatically increased with meloxicam treatment. Conclusion: Low epidermal growth factor receptor expression is a common feature of fatty liver disease. Meloxicam restores epidermal growth factor receptor expression in steatotic hepatocytes. Meloxicam pretreatment may be applied to improve outcome after fatty liver resection or transplantation with steatotic graft.

AB - Background: Patients with fatty liver have delayed regenerative responses, increased hepatocellular injury, and increased risk for perioperative mortality. Currently, no clinical therapy exists to prevent liver failure or improve regeneration in patients with fatty liver. Previously we demonstrated that obese mice have markedly reduced levels of epidermal growth factor receptor in liver. We sought to identify pharmacologic agents to increase epidermal growth factor receptor expression to improve hepatic regeneration in the setting of fatty liver resection. Methods: Lean (20% calories from fat) and diet-induced obese mice (60% calories from fat) were subjected to 70% or 80% hepatectomy. Results: Using the BaseSpace Correlation Engine of deposited gene arrays we identified agents that increased hepatic epidermal growth factor receptor. Meloxicam was identified as inducing epidermal growth factor receptor expression across species. Meloxicam improved hepatic steatosis in diet-induced obese mice both grossly and histologically. Immunohistochemistry and Western blot analysis demonstrated that meloxicam pretreatment of diet-induced obese mice dramatically increased epidermal growth factor receptor protein expression in hepatocytes. After 70% hepatectomy, meloxicam pretreatment ameliorated liver injury and significantly accelerated mitotic rates of hepatocytes in obese mice. Recovery of liver mass was accelerated in obese mice pretreated with meloxicam (by 26% at 24 hours and 38% at 48 hours, respectively). After 80% hepatectomy, survival was dramatically increased with meloxicam treatment. Conclusion: Low epidermal growth factor receptor expression is a common feature of fatty liver disease. Meloxicam restores epidermal growth factor receptor expression in steatotic hepatocytes. Meloxicam pretreatment may be applied to improve outcome after fatty liver resection or transplantation with steatotic graft.

UR - http://www.scopus.com/inward/record.url?scp=85040543818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040543818&partnerID=8YFLogxK

U2 - 10.1016/j.surg.2017.11.029

DO - 10.1016/j.surg.2017.11.029

M3 - Article

C2 - 29361369

AN - SCOPUS:85040543818

JO - Surgery

JF - Surgery

SN - 0039-6060

ER -